• CDC
  • Heart Failure
  • Cardiovascular Clinical Consult
  • Adult Immunization
  • Hepatic Disease
  • Rare Disorders
  • Pediatric Immunization
  • Implementing The Topcon Ocular Telehealth Platform
  • Weight Management
  • Screening
  • Monkeypox
  • Guidelines
  • Men's Health
  • Psychiatry
  • Allergy
  • Nutrition
  • Women's Health
  • Cardiology
  • Substance Use
  • Pediatrics
  • Kidney Disease
  • Genetics
  • Complimentary & Alternative Medicine
  • Dermatology
  • Endocrinology
  • Oral Medicine
  • Otorhinolaryngologic Diseases
  • Pain
  • Gastrointestinal Disorders
  • Geriatrics
  • Infection
  • Musculoskeletal Disorders
  • Obesity
  • Rheumatology
  • Technology
  • Cancer
  • Nephrology
  • Anemia
  • Neurology
  • Pulmonology

Estradiol Levels Predict Fracture Risk During the Menopausal Transition

Slideshow

Authors of a new study found that estradiol levels can be used to predict fracture risk among women during the menopausal transition. 

Related Content
CPAP Treatment and Hypertensive Adverse Outcomes in Pregnancy: Daily Dose / image credit: ©New Africa/AdobeStock

CPAP Treatment and Hypertensive Adverse Outcomes in Pregnancy: Daily Dose

Sydney Jennings
September 6th 2024
Article

Your daily dose of the clinical news you may have missed.

CPAP Therapy May Reduce Hypertensive Disorders of Pregnancy by More than 30%: Meta-Analysis / image credit blood pressure: ©H_Ko/stock.adobe.com

CPAP Therapy May Reduce Hypertensive Disorders of Pregnancy by More than 30%: Meta-Analysis

Grace Halsey
August 26th 2024
Article

Obstructive sleep apnea during pregnancy increases risk for gestational hypertension and preeclampsia; CPAP therapy may lower risk significantly.

Bayer Submits NDA to FDA For Elinzanetant for Treatment of Moderate-to-Severe Hot Flashes in Women with Menopause / Image credit: ©highwaystarz/AdobeStock

Bayer Submits NDA to FDA for Elinzanetant for Treatment of VMS

Sydney Jennings
August 6th 2024
Article

The submission is based on data from OASIS trials that showed elinzanetant significantly reduced the frequency and severity of moderate-to-severe VMS associated with menopause.

FDA Approves First Orally Disintegrating Tablet for Birth Control: Daily Dose / image credit: ©New Africa/AdobeStock

FDA Approves First Orally Disintegrating Tablet for Birth Control: Daily Dose

Sydney Jennings
August 5th 2024
Article

Your daily dose of the clinical news you may have missed.

Unplanned Pregnancy, Recent Relocation Among Top Barriers to Early Prenatal Care in US / Image credit: ©JenkoAtaman/AdobeStock

Unplanned Pregnancy, Recent Relocation Among Top Barriers to Early Prenatal Care in US

Sydney Jennings
July 31st 2024
Article

Findings from a recent study highlight the need for targeted interventions to improve access to prenatal care for vulnerable populations.

FDA Approves Femlyv, First Orally Disintegrating Tablet for Birth Control July 25, 2024

FDA Approves Femlyv, First Orally Disintegrating Tablet for Birth Control

Celeste Krewson
July 25th 2024
Article

Femlyv (norethindrone acetate and ethinyl estradiol) may expand access to contraception as an option for individuals with swallowing difficulties.

© 2024 MJH Life Sciences

All rights reserved.